AARDEX Group

publication

Data Science and Medication Adherence

Examining the Role of Data Science in Understanding Patient Behaviors.

Our latest article in Applied Clinical Trials Online discusses the Role of Data Science and Understanding Patient Behavior. … Read More

Our latest article in PMPS discusses how non-adherence to medication has been costing lives and money for decades but SmartPackaging solutions are now solving the age-old problem.

This article is taken from Pharmaceutical Manufacturing and Packing Sourcer February 2021, pages 46-49. © Samedan Ltd

AARDEX announces the world’s first DIGITAL MEDICATION ADHERENCE MONITORING solution fully integrated in the clinical trial platform by a top 10 pharma company.

AARDEX is proud to announce the integration of its MEMS® Adherence Software by a major pharmaceutical company. It’s the first end-to-end integration of electronically compiled dosing histories using smart packages from interactive response technology (IRT) into electronical data capture systems … Read More

AARDEX Group announces the opening of a new office in the U.S.

By establishing itself in the U.S., the Group aims to strengthen its business and maintain its position as market leader in digital adherence monitoring systems. Joe Keenan will lead the business development for the pharma and biotech industry in North America. … Read More

Using data science to detect key changes in medication intake behaviors.

Electronic monitoring, a digital technology based on smart packages, enables the most objective and precise adherence monitoring. By using an evidence-based digital adherence monitoring system, Sponsors and HCPs improve drug efficacy by managing patient adherence to the medications. In this … Read More

How smart packages enable digital medication adherence monitoring for successful clinical trials?

50 % of patients involved in clinical trials do not take their medication as prescribed, resulting in underestimated drug efficacy and delayed approval of the investigational product. Poor medication adherence is thus a threat to drug development. Stop using unreliable … Read More

How the EMERGE guideline on medication adherence can improve the quality of clinical trials

Recently, the FDA (Mar 2019) and the EMA (Feb 2020) have finalized guidances to monitor and mitigate the risk of patient non-adherence to the treatments tested in clinical trials. Under the auspices of the International Society for Medication Adherence (ESPACOMP), an … Read More